Ketotifen-d3

Ketotifen-d3 (HC 20-511-d3) is deuterium labeled Ketotifen. Ketotifen (HC 20-511) is an orally active second-generation noncompetitive histamine 1 (H1) receptor blocker and mast cell stabilizer. Ketotifen can block 6-phosphogluconate dehydrogenase (PGD) in vitro. Ketotifen also has antiviral activity against SARS-CoV-2 and Influenza virus. Ketotifen can be used to the research of autoimmune encephalomyelitis (EAE) and asthma attack prevention[1][2][3][4].

Product Specifications

CAS Number

[126939-17-1]

Product Name Alternative

HC 20-511-d3

UNSPSC

12352005

Target

Endogenous Metabolite; Histamine Receptor; Influenza Virus; Isotope-Labeled Compounds; SARS-CoV

Related Pathways

Anti-infection; GPCR/G Protein; Immunology/Inflammation; Metabolic Enzyme/Protease; Neuronal Signaling; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Infection; Endocrinology; Inflammation/Immunology; Cancer

Smiles

O=C1C2=C(C=CS2)/C(C3=CC=CC=C3C1)=C4CCN(CC\4)C([2H])([2H])[2H]

Molecular Formula

C19H16D3NOS

Molecular Weight

312.44

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Klooker TK, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 2010 Sep;59 (9) :1213-21.|[3]Zhang H, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020;35 (1) :1322-1330.|[4]Kiani P, et al. In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2. Viruses. 2021 Mar 26;13 (4) :558.|[5]Enkirch T, et al. Identification and in vivo Efficacy Assessment of Approved Orally Bioavailable Human Host Protein-Targeting Drugs With Broad Anti-influenza A Activity. Front Immunol. 2019 Jun 5;10:1097.|[6]Pinke KH, et al. Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy? Neurotherapeutics. 2020 Jan;17 (1) :218-234.